[
    [
        {
            "time": "2021-08-11",
            "original_text": "A股早报2021年8月11日星期三",
            "features": {
                "keywords": [
                    "A股",
                    "早报",
                    "2021年8月11日"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股早报2021年8月11日星期三",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-07-27",
            "original_text": "华兰生物：7月27日，公司首批200万支四价流感疫苗发往河南等地",
            "features": {
                "keywords": [
                    "华兰生物",
                    "四价流感疫苗",
                    "河南"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物：7月27日，公司首批200万支四价流感疫苗发往河南等地",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华兰生物：目前公司和广东恩宝已启动相关疫苗的临床试验相关工作",
            "features": {
                "keywords": [
                    "华兰生物",
                    "广东恩宝",
                    "临床试验",
                    "疫苗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华兰生物：目前公司和广东恩宝已启动相关疫苗的临床试验相关工作",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "市场格局加速重塑，谁将成为中国的“疫苗之王”？",
            "features": {
                "keywords": [
                    "市场格局",
                    "疫苗之王"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "市场格局加速重塑，谁将成为中国的“疫苗之王”？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华兰生物：目前公司的所有产品均未列入医保集采",
            "features": {
                "keywords": [
                    "华兰生物",
                    "医保集采"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华兰生物：目前公司的所有产品均未列入医保集采",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]